

PrimePath™ SARS-CoV-2 VLP-RNA Control

Catalog No.	Amount	Lot Number
638344	Each	2301120

Description

PrimePath SARS-CoV-2 VLP-RNA Control is a highly stable, ribonuclease-resistant encapsulated RNA. The virus-like particles (VLP) that encapsulate a portion of the SARS-CoV-2 N gene can be used as a control in every step of an RNA molecular testing workflow, including extraction, reverse transcription, amplification, and detection. PrimePath SARS-CoV-2 VLP-RNA fits into any standard viral RNA extraction protocol or can simply be heat lysed at 85°C for 5 min to extract the RNA.

Package Contents

- 50 µl PrimePath SARS-CoV-2 VLP-RNA Control
- 4 x 1 ml EASY Dilution (for Real Time PCR)

Target Sequence

```
ATGTCGTGATAATGGACCCCAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCA
GTAACCAGAAATGGAGAAGGAACTGATTACAAACATTGGCCGCAAATTGCACAATTTGCCCCAGCGCTTCAGCGTT
CTTCGGAATGTCGCGCATTGGCATGCTTCTGCTGCAGATTTGGATGATTTCTCAAACAATTGCAACAATCCATGA
GCAGTGCTGACTCAACTCAGGCCTAA
```

Storage Conditions

- Store at -20°C.

Expiration Date

- JAN 31, 2025

Shipping Conditions

- Dry ice

Product Documents

Documents for our products are available for download at takarabio.com/manuals

The following documents apply to this product:

- PrimePath SARS-CoV-2 VLP-RNA Control Protocol-At-A-Glance

Quality Control Data

Concentration/Quantification

Droplet digital PCR was performed on PrimePath SARS-CoV-2 VLP-RNA Control and was found to have a concentration of 3.64×10^6 copies/µl.

Takara Bio USA, Inc.

2560 Orchard Parkway, San Jose, CA 95131, USA

U.S. Technical Support: technical_support@takarabio.com

United States/Canada 800.662.2566 (022823)	Asia Pacific +1.650.919.7300	Europe +33.(0)1.3904.6880	Japan +81.(0)77.565.6999
--	---------------------------------	------------------------------	-----------------------------

Certificate of Analysis

Cat. No. 638344

PrimePath SARS-CoV-2 VLP-RNA Control

In addition, PrimePath SARS-CoV-2 VLP-RNA Control was tested for the following specifications:

QC Test	Description	QC Specification
Sequence accuracy	Sanger sequencing to verify exact nucleic acid sequence present	No mutations in sequence identified
Integrity	RT-qPCR to determine the percentage of intact VLP-RNA capsules	>90% of VLP-RNA particles are calculated as intact
Linearity	RT-qPCR to determine presence of impurities	Standard curve analysis has an efficiency range of 85–115% and an $R^2 >0.95$
Expression	Western blot for VLP-RNA capsule protein	Presence of clear, single band at ~28 kD

It is certified that this product meets the above specifications, as reviewed and approved by the Quality Department.

PrimePath™ SARS-CoV-2 VLP-RNA Control

CATALOG NO.

638344

NOTICE TO PURCHASER:

Our products are to be used for **Research Use Only**. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Your use of this product is also subject to compliance with the licensing requirements, listed below if applicable, and described on the product's web page at <http://www.takarabio.com>. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

TRADEMARKS:

©2023 Takara Bio Inc. All Rights Reserved.

All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions.

Takara Bio USA, Inc.

2560 Orchard Parkway, San Jose, CA 95131, USA

U.S. Technical Support: technical_support@takarabio.com

United States/Canada

Asia Pacific

Europe

Japan

800.662.2566

+1.650.919.7300

+33.(0)1.3904.6880

+81.(0)77.565.6999

2/28/2023